콘텐츠로 건너뛰기
Merck
  • Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

Annals of neurology (2006-12-29)
Matthew Townsend, James P Cleary, Tapan Mehta, Jacki Hofmeister, Sylvain Lesne, Eugene O'Hare, Dominic M Walsh, Dennis J Selkoe
초록

Despite progress in defining a pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, orally bioavailable compounds that prevent its effects on hippocampal synaptic plasticity and cognitive function have not yet emerged. A particularly attractive therapeutic strategy is to selectively neutralize small, soluble Abeta oligomers that have recently been shown to mediate synaptic dysfunction. Using electrophysiological, biochemical, and behavioral assays, we studied how scyllo-inositol (AZD-103; molecular weight, 180) neutralizes the acutely toxic effects of Abeta on synaptic function and memory recall. Scyllo-inositol, but not its stereoisomer, chiro-inositol, dose-dependently rescued long-term potentiation in mouse hippocampus from the inhibitory effects of soluble oligomers of cell-derived human Abeta. Cerebroventricular injection into rats of the soluble Abeta oligomers interfered with learned performance on a complex lever-pressing task, but administration of scyllo-inositol via the drinking water fully prevented oligomer-induced errors. A small, orally available natural product penetrates into the brain in vivo to rescue the memory impairment produced by soluble Abeta oligomers through a mechanism that restores hippocampal synaptic plasticity.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
scyllo-Inositol, ≥98%